Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IWWM-11 2022 | Future considerations for the treatment of Waldenström’s macroglobulinemia

Patrizia Mondello • 28 Oct 2022
IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia BTK inhibitors

Patrizia Mondello, MD, PhD, Mayo Clinic, Rochester, MN, briefly discusses the importance of improving treatment options for patients with Waldenström’s macroglobulinemia (WM), and the potential role of combination approaches and immunotherapies. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Patrizia Mondello

1:32
The importance of understanding the TME & using this to guide treatment for B-cell lymphomas
Patrizia Mondello • 16 Jun 2023
4:06
Exploring the impact of magnesium levels on the outcomes of patients with LBCL receiving axi-cel
Patrizia Mondello • 16 Jun 2023
2:37
Molecular clusters and tumor-immune drivers of IgM monoclonal gammopathies
Patrizia Mondello • 28 Oct 2022
1:05
The importance of improving precision therapy in B-cell lymphomas
Patrizia Mondello • 28 Oct 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals